Antengene (SEHK:6996) - Aktienkurs, Nachrichten und Analyse

6996 Aktienübersicht

Antengene Corporation Limited ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung neuartiger Onkologie-Therapien im Großraum China und international beschäftigt.

Über das Unternehmen

6996 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 61.52%

Die Erträge sind in den letzten 5 Jahren um 9.6% pro Jahr gestiegen.

Risikoanalyse

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung (HK$661M)

Antengene Corporation Limited Wettbewerber

Pak Fah Yeow International

SEHK:239

HK$766.6m

Tianda Pharmaceuticals

SEHK:455

HK$559.0m

Fusen Pharmaceutical

SEHK:1652

HK$739.3m

JBM (Healthcare)

SEHK:2161

HK$861.1m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Antengene
Historische Aktienkurse
Aktueller Aktienkurs	HK$0.75
52-Wochen-Hoch	HK$2.25
52-Wochen-Tief	HK$0.73
Beta	0.85
11 Monat Veränderung	-22.68%
3 Monate Veränderung	-18.48%
1 Jahr Veränderung	-55.36%
33 Jahre Veränderung	-96.05%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-95.90%

Aktuelle Nachrichten und Updates

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22

Aktionärsrenditen

	6996	HK Pharmaceuticals	HK Markt
7D	-7.4%	-0.6%	-0.8%
1Y	-55.4%	-7.4%	-1.1%

Rendite im Vergleich zur Industrie: 6996 unter dem Niveau der Branche Hong Kong Pharmaceuticals, die im vergangenen Jahr eine Rendite von -7.7% erzielte.

Rendite vs. Markt: 6996 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 2.7 erzielte.

Preisvolatilität

Is 6996's price volatile compared to industry and market?
6996 volatility
6996 Average Weekly Movement	7.3%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 6996Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: 6996Die wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2017	201	Jay Mei	www.antengene.com

Antengene Corporation Limited ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung neuartiger Onkologie-Therapien im Großraum China und international beschäftigt. Zu den vermarkteten Produkten des Unternehmens gehört ATG-010 (Selinexor), ein oraler SINE-Wirkstoff zur Behandlung verschiedener hämatologischer Malignome und solider Tumore, darunter das rezidivierte/refraktäre multiple Myelom (rrMM), das rezidivierte/refraktäre diffuse großzellige B-Zell-Lymphom und das multiple Myelom (MM) bei erwachsenen Patienten in Festlandchina, Singapur, Australien, Hongkong, Macao und Taiwan. Seine Produktkandidaten in der Spätphase umfassen ATG-008 (Onatasertib), einen mTOR-Kinase-Hemmer zur Behandlung von Gebärmutterhalskrebs und anderen fortgeschrittenen soliden Tumoren.

Antengene Corporation Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Antengene im Vergleich zum Marktanteil des Unternehmens?
6996 grundlegende Statistiken
Marktanteil	HK$506.17m
Gewinn(TTM)	-HK$624.57m
Umsatz(TTM)	HK$72.33m

7.0x

Kurs-Umsatz-Verhältnis

-0.8x

Kurs-Gewinn-Verhältnis

Ist 6996 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
6996 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥67.31m
Kosten der Einnahmen	CN¥12.29m
Bruttogewinn	CN¥55.01m
Sonstige Ausgaben	CN¥636.20m
Umsatz	-CN¥581.18m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.86
Bruttomarge	81.74%
Nettogewinnspanne	-863.51%
Schulden/Eigenkapital-Verhältnis	15.7%

Wie hat sich 6996 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

6996 Aktienübersicht

Belohnungen

Risikoanalyse

Antengene Corporation Limited Wettbewerber

SEHK:239

HK$766.6m

SEHK:455

HK$559.0m

SEHK:1652

HK$739.3m

SEHK:2161

HK$861.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Recent updates

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

New minor risk - Share price stability

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Antengene Corporation Limited Announces Executive Changes

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Less than half of directors are independent

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Less than half of directors are independent

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Erträge & Einnahmen